The STAR trial: Evaluation of a care pathway for patients with long-term pain after knee replacement
Following the publication of the STAR trial results, one of the Exeter participants was featured on BBC news and BBC Spotlight yesterday (2:25 into the broadcast):
NOVAVAX STUDY: A PHASE 3, RANDOMISED, OBSERVER-BLINDED, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SARS-COV-2 RECOMBINANT SPIKE PROTEIN NANOPARTICLE VACCINE (SARS-COV-2 RS) WITH MATRIX-M1TM ADJUVANT IN ADULT PARTICIPANTS 18-84 YEARS OF AGE IN THE UNITED KINGDOM.
(MHRA) has authorised Novavax’s COVID-19 vaccine for use in the UK. The article linked below recognises the role that the teams provided.
UK-ROX: Evaluating the clinical and cost-effectiveness of a conservative approach to oxygen therapy for invasively ventilated adults in intensive care.
4th Highest recruitment in the UK. Great work team!
|Site Name||Overall Recruitment|
|Sunderland Royal Hospital||232|
|Grange University Hospital||194|
|Queen Alexandra Hospital||122|
|Royal Devon and Exeter Hospital||115|
GenOMICC: Genetics Of Mortality In Critical Care
Dear Collaborators, co-authors and recruiting sites,
I’m delighted to say that our latest GenOMICC manuscript has (at last!) been accepted for publication in Nature. Including the HGIv5 paper, this is the third Nature paper from the GenOMICC study, and reports an additional 16 new robust genetic associations with Covid severity. Together with the four associations from our first report, and three findings from other studies, this brings the total number of replicated associations to 23.
Two years on from the first Covid patients in the UK, it is still true that the majority of knowledge about host genetics in Covid severity comes directly from GenOMICC, including multiple therapeutic targets under active investigation now. This is a direct consequence of your dedication and diligence in extremely difficult circumstances over the past two years. Of course, this is just the first step, and we continue to work to translate these findings into meaningful clinical impact, to fulfil the expectations of the tens of thousands of patients who have contributed, many of whom did not survive their illness.
The accepted manuscript is essentially the same as the last version I shared, with many minor changes from the editorial team, and can be found here:
We’ve also agreed to publish our responses to peer review, which were very fastidious, thanks in particular to the excellent work of Thanos, Erola and Konrad, so it is nice that those extra analyses will see the light of day.
Many thanks for all of the hard work that got us here, and thanks for your ongoing efforts to recruit more patients into the study. For Covid, sepsis, flu and other forms of critical illness, the calculation remains the same: the more patients we recruit, the better the chance of finding a new therapeutic target.
J Kenneth Baillie BSc(Hons) MBChB PhD FRCA FRCP FFICM
EFC17262 / URSA study: A Phase 3, randomized, double-blind, efficacy and safety, 2-arm, parallel-group study comparing SAR442168 to placebo in adult participants with generalized myasthenia gravis.
Dear Dr. Harrower and team,
On behalf of the entire EFC17262 / URSA study team, we would like to extend our sincere thanks to you for your notable and commendable efforts so far.
Your study site and entire team randomised the 2nd participant worldwide in the EFC17262 / URSA study. Two participants are randomised so far in the study, and both are from UK sites. This is a wonderful achievement.
Excellent work team!